Leuthold Group LLC Buys Shares of 100,358 GSK PLC Sponsored ADR $GSK

Leuthold Group LLC bought a new stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 100,358 shares of the pharmaceutical company’s stock, valued at approximately $4,922,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Fisher Asset Management LLC boosted its stake in GSK by 2.8% during the 3rd quarter. Fisher Asset Management LLC now owns 32,227,615 shares of the pharmaceutical company’s stock valued at $1,390,944,000 after purchasing an additional 889,210 shares during the period. Brighton Jones LLC acquired a new position in GSK during the 4th quarter valued at about $528,000. Prime Capital Investment Advisors LLC boosted its stake in GSK by 182.7% during the 4th quarter. Prime Capital Investment Advisors LLC now owns 30,188 shares of the pharmaceutical company’s stock valued at $1,480,000 after purchasing an additional 19,509 shares during the period. Farther Finance Advisors LLC boosted its stake in GSK by 146.6% during the 4th quarter. Farther Finance Advisors LLC now owns 29,529 shares of the pharmaceutical company’s stock valued at $1,448,000 after purchasing an additional 17,553 shares during the period. Finally, Great Lakes Advisors LLC boosted its stake in GSK by 54.0% during the 3rd quarter. Great Lakes Advisors LLC now owns 49,279 shares of the pharmaceutical company’s stock valued at $2,127,000 after purchasing an additional 17,273 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Down 2.5%

GSK stock opened at $49.66 on Friday. GSK PLC Sponsored ADR has a 52 week low of $35.45 and a 52 week high of $61.69. The company has a market capitalization of $100.78 billion, a price-to-earnings ratio of 12.91, a price-to-earnings-growth ratio of 2.53 and a beta of 0.38. The firm’s 50-day moving average is $54.33 and its two-hundred day moving average is $52.07. The company has a current ratio of 0.79, a quick ratio of 0.52 and a debt-to-equity ratio of 0.80.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 9th. Investors of record on Friday, May 15th will be issued a $0.44 dividend. This represents a $1.76 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date is Friday, May 15th. GSK’s payout ratio is presently 48.83%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Barclays reissued an “underweight” rating on shares of GSK in a research note on Friday, February 20th. Wall Street Zen lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 7th. Weiss Ratings raised shares of GSK from a “hold (c+)” rating to a “buy (b)” rating in a research note on Friday, May 1st. TD Cowen reissued a “hold” rating on shares of GSK in a research note on Monday, February 9th. Finally, Citigroup restated a “neutral” rating on shares of GSK in a research report on Monday, February 9th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $53.00.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.